Canadian Cancer Trials Group Bulletins

General


Trial Closed to Accrual

Canadian Cancer Trials Group IND.187 -- A Phase I Study of AZD2281 in Combination with Irinotecan in Patients with Locally Advanced or Metastatic Incurable Colorectal Cancer -- was closed to accrual on March 8, 2012 after establishing the recommended phase II dose.

It is anticipated the final patient will have completed treatment in May of 2012 and the Final Analysis will be done for, or prior to, Fall 2012.

Thanks to all participating centres, staff and patients for their participation to help ensure this trial was able to close successfully.